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Most circulating human gamma delta T cells are Vγ9Vδ2 T cells. Their hallmark is the
expression of T cell antigen receptors (TCR) whose γ-chains show a Vγ9-JP (Vγ2-Jγ1.2)
rearrangement and are paired with Vδ2-containing δ-chains, a dominant TCR configuration,
which until recently seemed to occur in primates only. Vγ9Vδ2T cells respond to phospho-
antigens (PAg) such as (E )-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), which
is produced by many pathogens and isopentenyl pyrophosphate (IPP), which accumulates
in certain tumors or cells treated with aminobisphosphonates such as zoledronate. A pre-
requisite for PAg-induced activation is the contact of Vγ9Vδ2 T cells with cells expressing
butyrophilin-3 A1 (BTN3A1). We will first critically review models of how BTN3 might act in
PAg-mediated Vγ9Vδ2 T cell activation and then address putative co-evolution of Vγ9, Vδ2,
and BTN3 genes. In those rodent and lagomorphs used as animal models, all three genes
are lost but a data-base analysis showed that they emerged together with placental mam-
mals. A strong concomitant conservation of functional Vγ9, Vδ2, and BTN3 genes in other
species suggests co-evolution of these three genes. A detailed analysis was performed
for the new world camelid alpaca (Vicugna pacos). It provides an excellent candidate for
a non-primate species with presumably functional Vγ9Vδ2 T cells since TCR rearrange-
ments share features characteristic for PAg-reactive primate Vγ9Vδ2 TCR and proposed
PAg-binding sites of BTN3A1 have been conserved. Finally, we analyze the possible func-
tional relationship between the butyrophilin-family member Skint1 and the γδTCR-V genes
used by murine dendritic epithelial T cells (DETC). Among placental mammals, we identify
five rodents, the cow, a bat, and the cape golden mole as the only species concomitantly
possessing potentially functional homologs of murineVγ3,Vδ4 genes, and Skint1 gene and
suggest to search for DETC like cells in these species.
Keywords: γδT cell,Vγ9Vδ2T cell, phosphoantigen, BTN3, alpaca, co-evolution, DETC and Skint1
αβ T CELLS AND γδ T CELLS
Jawed vertebrates (Gnathostomata) possess lymphocytes express-
ing Ig-domain containing antigen-receptors, whose highly diverse
antigen-binding sites are generated by RAG-dependent somatic
recombination of genes encoding for an antigen-binding variable-
domain. Such receptors are broadly classified into three types. αβ
and γδ T cell antigen receptors (TCR), which are encoded by αβ
and γδ genes, respectively, and the B cell antigen receptors, which
are encoded by immunoglobulin heavy and light chain genes (1–
3). The exact sequence of emergence of the antigen-receptor genes
is controversial. One view is that the γδ TCR encoding genes
originally constituted a receptor for soluble antigens, which is
Abbreviations: aa, amino acids; BTN, butyrophilin; BTN3A1-ED, butyrophilin-3
A1 extracellular domain; BTN3A1-ID, butyrophilin-3 A1 intracellular domain; Chr.
6, chromosome 6; DETC, dendritic epidermal T cells; DOXP, 1-deoxy-d-xylulose 5-
phosphate pathway; FPPS, farnesyl diphosphate synthase; HMBPP, (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate; IPP, isopentenyl pyrophosphate; mAb, mon-
oclononal antibody; MEP, 2-C-methyl-d-erythritol 4-phosphate pathway; PAg,
phosphoantigen; VLR, variable leukocyte receptors.
primordial to the MHC-restricted αβ TCR, BCR, and antibodies
(2, 4). Alternatively, αβ and γδ TCR-genes may have emerged
from a common ancestor (5). An interesting case of convergent
evolution has occurred in jawless vertebrates (Agnatha). Their
lymphocytes express antigen-receptors completely distinct from
those of Gnathostomata both in terms of molecular composition
(leucine rich repeats instead of Ig domains) and genetic basis of
diversity generation [Cytidine deaminase (AID) dependent gene
conversion]. Three distinct lineages of lymphocytes expressing dis-
tinct antigen receptors variable leukocyte receptors (VLR) (6, 7)
have been identified: T-like lymphocytes maturing in the thymus
express VLRA and VLRC while B-like lymphocytes produce VLRB
as soluble antigen-receptors (8).
Among T cells, those which confer adaptive immunity are
MHC-restricted T cells. They express αβ TCR, which bind to
complexes of polymorphic MHC molecules and peptide anti-
gens. Their diversity is generated by RAG-mediated recombina-
tion of V(D)J genes of both chains. The diversity of their third
complementarity-determining regions (CDR3) which are encoded
by the VαJα and VβDβJβ transition is further increased by joining
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flexibility and insertion of P and N-nucleotides. The final com-
position of TCR specificities (T cell repertoire) is shaped by
intrathymic positive and negative selection guided by anatom-
ically controlled presentation of peptide-MHC complexes and
avidity of binding of the emerging TCR to those complexes (9).
A highly conserved (2, 3), although not absolute feature in all
vertebrate species (10), is the division of mature T cells as in
MHC-class I restricted CD8 T cells, which exert killer function
and MHC-class II restricted CD4 T cells, which regulate immune
functions (2, 3). In spite of a likely co-evolution of the pep-
tide presenting MHC molecules with Vα and Vβ TCR genes,
it is not possible to predict MHC-class restriction or antigen-
specificity of a given T cell from usage of certain TCR genes
(11–13).
Alongside “conventional” MHC-restricted αβ T cells, several
T cell populations exist with specificities for ligands other than
MHC-peptide complexes. These “non-conventional” T cells can
express αβ or γδ TCR. The generation of their TCR diversity
follows the same genetic mechanisms as for MHC-restricted αβ
TCR but in contrast to MHC-restricted T cells TCR-gene usage
can be predictive for ontogeny, homing, and effector functions
and is used to define distinct T cell subpopulations (12, 14–17).
The best understood population of non-conventional T cells are
the CD1d-restricted invariant NKT cells (17, 18). Their TCRα
chains are invariant with a characteristic VαJα rearrangement
and pair with β-chains of restricted Vβ gene usage. The iNKT
TCRs bind in a highly conserved manner to complexes of the
non-polymorphic MHC-class I like CD1d molecule and micro-
bial or host cell glycolipids. Thus, functionally they resemble
pattern recognition receptors of innate immune cells, which do
not discriminate between highly variable antigens but recognize
molecular patterns (17, 18). In contrast to MHC-restricted αβ
T cells, which at least in mammals differentiate into CD8 killer
T cells and CD4 helper and regulatory T cells, subpopulations
of non-conventional T cells vary strongly between phylogenetic
groups, e.g., many mammals lack iNKT cells as well as the restrict-
ing CD1d molecule (19, 20) but even closely related species such as
mouse and rat differ dramatically in terms of iNKT-cell frequency
although the respective genes for iNKT TCR and CD1d are highly
conserved (21).
γδ T cells differ strongly between taxa. This difference can be
rather global as in case of γδ T cells whose frequencies among
blood T cells vary between 1 and 5% in man and mouse to
50% in ruminants (22). The presence or absence of entire pop-
ulations defined by their TCR gene usage is even more striking
(14, 23–25). Two such cases are addressed in this review: at first
the human Vγ9Vδ2 T cells, which have so far only been found in
higher primates (26). For their function, associated with various
microbial and host metabolites, the molecule butyrophilin-3A1 is
mandatory and this article will address the putative function of
BTN3A1 and current evidence for a co-evolution of Vγ9Vδ2 TCR
and BTN3A1. Secondly, we provide a first analysis of phylogeny
of Vγ and Vδ genes constituting the TCR of murine dendritic epi-
dermal T cell receptor (DETC) (27–30) and Skint1, a member of
the butyrophilin family, which is critical during the ontogeny and
function of these cells (31).
Vγ9Vδ2 T CELLS: TCR AND PHOSPHOANTIGEN REACTIVITY
The vast majority of human blood γδ T cells respond to
so called “Phosphoantigens” (PAg) (32–34). Their TCR share
a characteristic Vγ9JP (alternatively designated as Vγ2Jγ1.2)
rearrangement (35–38) and Vδ2-containing chains (35) bear-
ing one of the hydrophobic amino acids (38, 39): Leucine (L),
Isoleucine (I), Valine (V), or Glycine (G) at position 97. Unless
explicitly mentioned PAg-reactive T cells and Vγ9Vδ2 T cells will
be used as synonyms in this article.
Freshly isolated Vγ9Vδ2 T cells share functional features with
TH1 cells, CD8 T cells, and NK cells (40) but upon culture they
can differentiate to TH17 like (41), and to professional antigen-
presenting cells (42). Apart from killing or cytokine release, they
promote and regulate immune responses by crosstalk with den-
dritic cells (43), NK cells (44), and monocytes (45). Numerous
preclinical and clinical studies demonstrated their therapeutic
potential for treatment of tumors (46, 47) and infection (48, 49).
The antigen-dependent activation of Vγ9Vδ2 T cells is strongly
modulated by additional receptors (50) including inhibitory and
activating NK-cell receptors (51, 52). In case of NKG2D even a
direct triggering of some effector functions is possible (53).
PAg are products of isoprenoid synthesis, which specifically
activate Vγ9Vδ2 T cells. The building blocks of isoprenoid synthe-
sis are isopentenyl pyrophosphate (IPP) and its isomer dimethylal-
lyl pyrophosphate. Both are weak PAg (54, 55) and 1000- to 10000-
fold less potent than the strongest naturally occurring PAg (E)-4-
Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) (26, 55,
56). HMBPP is the immediate precursor in the synthesis of IPP
by the non-mevalonate pathway also known as DOXP, MEP, or
Rohmer pathway. The non-mevalonate-pathway is restricted to
eubacteria, cyanobacteria, plants, and apicomplexan protozoa (26,
56), which may have adopted this pathway by endosymbiosis of
precursors of chloroplasts and apicoplast, respectively (57, 58).
HMBPP is the driving force of a massive Vγ9Vδ2 T cell expan-
sion in infections with HMBPP producing parasites or bacteria,
which can lead to an increase of Vγ9Vδ2 T cells from 1 to 5%
of blood T cells to more than 50% (26, 49). In mammals and
most other animals, IPP is synthesized via the mevalonate path-
way whose manipulation can render human cells into Vγ9Vδ2
T cell activators. Cells pulsed with aminobisphosphonates (e.g.,
zoledronate or pamidronate) become potent activators of primary
Vγ9Vδ2 T cells (59, 60) and of Vγ9Vδ2 TCR transductants (61)
most likely in consequence of IPP accumulation after inhibition
of the IPP metabolizing farnesyl diphosphate synthase (FPPS)
(59, 62). The same effects are seen by inhibiting expression of
FPPS (63, 64) and of isopentenyl diphosphate isomerase (64).
Other modes of activation by IPP accumulation are activation
(65) or over-expression of HMG-CoA reductase (66), which is
the rate-controlling enzyme upstream of IPP synthesis, and finally
inhibition of FPPS by alkylamines (67, 68).
Altogether the Vγ9Vδ2 TCR acts as a kind of pattern recogni-
tion receptor, which senses microbial infections as well as meta-
bolic changes found in transformed, infected, or drug treated host
cells (69). This reactivity can be harnessed clinically since remis-
sion of certain tumor entities after Vγ9Vδ2 T cell activation was
observed in clinical trials (46, 47, 59, 60) and it may even contribute
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to the beneficial effects of zoledronate seen upon treatment of
premenopausal women with early-stage breast cancer (70).
Some tumors such as the human B cell lymphoma Daudi
(71, 72) spontaneously activate Vγ9Vδ2 T cells. This activation
depends on intracellular accumulation of IPP and can be abol-
ished by statins, which inhibit the HMG-CoA reductase and
consequently also IPP synthesis (66). In contrast, still unclear
despite intensive investigation is the contribution and the mecha-
nistic basis of Vγ9Vδ2 T cell activation by the pro-apoptotic IPP
metabolite ApppI (triphosphoric acid 1-adenosin-50-yl ester 3-(3-
methylbut-3-enyl) ester), which is synthesized from IPP and AMP
by aminoacyl-tRNA-synthetases (73, 74). Also not clear is how
PAg-action is associated with the reported binding of the Vγ9Vδ2
TCR G115 to ectopically expressed F1-ATPase (74, 75).
BTN3 IS MANDATORY FOR PAg-MEDIATED ACTIVATION OF
Vγ9Vδ2 T CELLS
PAg act not as soluble molecules but need to be“presented”by cells
of human or primate origin (76). This can be seen as evidence for
species-specific molecules, which could be PAg-presenting mole-
cules and/or for molecules with special co-stimulatory or cell–cell
interaction mediating properties (77, 78). Attempts to identify
PAg-binding cell surface molecules by biochemical means, e.g.,
with the help of photo-activated PAg analogs have failed so far
(79, 80) although direct binding of tetramers of rhesus mon-
key Vγ9Vδ2 TCR to HMBPP pulsed primate dendritic cells was
reported (81).
The major breakthrough in defining species-specific molec-
ular requirements for Vγ9Vδ2 T cell activation by PAg was the
identification of the pivotal role of Butyrophilin 3 (BTN3) in
modulating PAg induced responses (82). BTN3 – also named
CD277 – is a membrane protein, which belongs to the butyrophilin
family and shares similarity with the B7 family (83). In human
beings, three isoforms of BTN3 named BTN3A1, BTN3A2, and
BTN3A3 exist whose genes localize to the telomeric end of the
MHC complex on the short arm of human chromosome 6 (84).
The extracellular domain of BTN3 (BTN3-ED) consists of an N-
terminal IgV-like domain (V-domain) and a membrane proximal
IgC-like domain (C-domain). The BTN3-ED of the three iso-
forms is extremely similar and cannot be discriminated by the
available antibodies (82, 83). The intracellular domain (ID) of
BTN3A1 and BTN3A3 belongs to the B30.2 family (85, 86) and is
often found in proteins involved in innate immunity. This includes
even molecules encoded by genes found in the hypothetical “proto
MHC” of placozoa, which form the most basal branch of Metazoa
(87). The BTN3A2 molecule has a truncated intracellular B30.2-
negative domain. So far the binding of BTN3 to Vγ9Vδ2 TCR
is controversial and a natural ligand or counter-receptor of the
BTN3-extracellular domain has not been found yet. Moreover,
CD277 antibodies modulate not only responses of Vγ9Vδ2 T cells
but also those of αβ T cells and NK cells (88, 89).
The first evidence for a critical role of BTN3 in Vγ9Vδ2 T cell
activation came from the agonistic action of the CD277-specific
monoclonal antibody (mAb) 20.1 on Vγ9Vδ2 T cells and other
CD277-specific antibodies, such as mAb 103.2, being antagonists
for PAg-mediated activation (82). Co-cultures of Vγ9Vδ2 T cells
or human Vγ9Vδ2 TCR transductants with mAb-pulsed BTN3
positive cells suggested that mAbs work by binding to stimula-
tory or target cells and not to the human γδ T cells. This was
formally proven by demonstrating that mAb 20.1 activates BTN3-
negative murine Vγ9Vδ2 TCR transductants in co-cultures with
human Raji cells (82). These reporter cells were either mouse
hybridoma BW58 (or C58α-β-) or the rat/mouse T cell hybridoma
53/4-transduced with a Vγ9Vδ2 TCR (TCR-MOP) (82, 90, 91).
Interestingly, the PAg-induced IL-2 production by both cell types
depends strictly on provision of strong co-stimulatory signal. This
can be achieved via ligation of a chimeric rat/mouse CD28 over-
expressed on the surface of the reporter cell by CD80 or CD86
on the stimulatory human cell, which can be of natural origin or
introduced by gene-transduction (91).
Activation by mAb 20.1 of TCR-MOP transductants but also of
primary responder cells is usually less efficient than PAg-induced
activation. Nevertheless, it has been shown for primary γδ T cells
that PAg- and mAb 20.1-induced activation are quite similar with
respect to TCR-mediated signals and phenotypic changes of the
cells (92). Furthermore, activation by mAb 20.1 is resistant to
statins and not accompanied by accumulation of IPP (80, 82).
MODELS OF PAg-ACTION: ALLOSTERIC CHANGE VS.
ANTIGEN PRESENTATION
At present, two major hypotheses to explain PAg-mediated acti-
vation of Vγ9Vδ2 T cells compete with each other. One suggests
that PAg-binding to the ID of BTN3A1 provokes changes in the
BTN3A1-ED either directly or with help of molecules recruited
by the ID. These events are accompanied by a reduced mobility
of cell surface BTN3A1 and are mandatory for binding of the
Vγ9Vδ2 TCR to BTN3A1 or associated molecule(s) alone or in
complex with BTN3. We will refer to this concept as the “allosteric
model” (82, 93, 94). The other concept suggests a direct bind-
ing of BTN3A1-PAg complexes to the Vγ9Vδ2 TCR and describes
BTN3A1 as an antigen-presenting molecule. This will be referred
to as the “antigen-presentation model” (95).
THE ALLOSTERIC MODEL
The work of Harly et al. (82) describes not only the general
importance of BTN3 for the PAg response but also that BTN3
isoforms differently support PAg-dependent Vγ9Vδ2 T cell acti-
vation while no such differences are found for mAb 20.1-induced
activation. Evidence was obtained by comparing BTN3 isoform
specific knockdown cells and transductants for their capacity to
induce PAg-dependent stimulation of primary Vγ9Vδ2 T cells.
The same pattern was found for the reduction in BTN3-cell
surface motility. In photobleaching experiments cells expressing
BTN3A1 or BTN3A2 constructs were compared. Aminobispho-
phonate (pamidronate) pulsed BTN3A1 but not BTN3A2 trans-
ductants showed a clear mevastatin-sensitive decrease in cell sur-
face mobility suggesting a PAg-induced BTN3 isoform related
effect. In contrast, for mAb 20.1 no differences between the iso-
forms were revealed although it decreased motility even stronger
than PAg. Further important insights came from structural and
functional characterization of the BTN3-ED (93). In this study,
soluble and crystallized BTN3-ED revealed no major difference
between the three BTN3 isoforms and could consequently not
help to explain their functional difference. More interestingly,
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these structural analyses revealed two types of BTN3-homodimers.
One had a symmetric paralleled structure where both chains were
fixed by interaction of their C-domains. The other one had an
asymmetric head to tail conformation with contacts between V-
and C-domain, respectively. Importantly, the agonistic but not the
antagonistic antibody favors formation of the symmetric dimer.
In addition, co-crystals with single chain (sc)20.1 revealed a con-
formational shift of the BTN3 dimer while sc103.2 has no such
effect. These results together with other data lead to model where
BTN3 and mAb 20.1 binds with a 2:1 stoichiometry and formed
a BTN3 lattice at the cells surface. In contrast, intact mAb 103.2
binds with 1:1 stoichiometry and is expected to inhibit formation
of such lattices while no inhibitory effects were seen with sc103.2.
Important clues how IDs might control PAg-dependent stim-
ulation comes from recent crystallographic and functional stud-
ies (94). This study first identified by deletion and amino acid
exchange mutants a region in the B30.2 domain as critical for
PAg-action. Crystallographic analysis identified then a positively
charged pocket in this region (the presumed contacts with the
PAg are marked in Figure 1B), which could accommodate a PAg.
Isothermal calorimetry demonstrated PAg-binding to recombi-
nant BTN3A1-ID, which was considerably stronger for HMBPP
than for IPP and was extinguished by the same mutants, which
abolished Vγ9Vδ2 TCR activation by respective BTN3 transduc-
tants. The importance of the pocket is further corroborated by
a single aa mutant in BTN3A1 (H351R), which destroyed the
PAg-binding to BTN3A1-ID, the PAg-dependent activation of
Vγ9Vδ2 T cells and the zoledronate-induced reduction of cell
surface motility. Altogether, evidence is provided that changes
induced by PAg-binding to BTN3A1-ID correlate with changes
seen in BTN3A1 cell surface motility and PAg-induced Vγ9Vδ2 T
cell activation (82, 93, 94). For illustrating the key points of this
hypothesis a simplified version of the“allosteric model” is depicted
in Figure 2A.
FIGURE 1 | Alignment of human BTN3A1 (V-C) and B30.2 domain.
(A) ClustalW2 amino acid alignment of V-C domains of human BTN3A1
extracellular domain with respective homologous sequence identified from
WGS database at NCBI. Underlined bold amino acids of human BTN3A1-ED
were predicted to interact with PAg (95). (B) ClustalW2 amino acid alignment
of intracellular B30.2 domains of human BTN3A1 with respective homologous
sequence. Underlined bold amino acids were of human BTN3A1-ID were
predicted to interact with PAg (94). Species were abbreviated as Hum,
Human; Aye, Aye-aye; GML, Gray mouse lemur; PTa, Philippine tarsier; Alp,
Alpaca; Kwh, Killer whales; Hor, Horse; Arm, Armadillo; Slo, Sloth.
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FIGURE 2 | Simplified sketches depicting the “allosteric model” and the
“antigen-presenting model.” Note that both models can be partially
combined. For reasons of simplicity involvement of hypothetical additional
molecule(s) (X) is only depicted were being absolutely necessary. (A) Sketch
representing the allosteric model describing possible events involved in PAg
mediated activation of Vγ9Vδ2 TCR. X – represents unidentified molecules,
which might involve in mechanism. (B) Schematic representation of
antigen-presentation model. TCR, T cell receptor; PAg, phosphoantigen.
THE ANTIGEN-PRESENTING MODEL
Vavassori et al. used a different approach to identify the species-
specific factor mandatory for PAg-mediated activation and
describe BTN3A1 as an antigen-presenting molecule (95). Their
approach takes advantage of the fact that mouse lacks a BTN3
ortholog. At first, murine reporter cells expressing a Vγ9Vδ2 TCR
were used to screen mouse-human hybrid cell lines for their capac-
ity to mediate PAg-dependent stimulation with the aim to map
this trait to a part of the human genome. By analysis of several
of such mouse-hybrid cell lines the telomeric 3–27 Mb region
of the human chromosome 6p was found to be mandatory for
PAg-presentation. This region comprises the entire MHC as well
as the BTN3A1 and BTN3A2 but not the BTN3A3 gene. Thus,
genomic localization of the mandatory gene(s) is fully consis-
tent with previously published data that BTN3A1 is mandatory
for PAg-mediated activation. The genetic evidence for BTN3A1
as candidate for the molecule involved was further confirmed by
knock down and over-expression experiments.
Interestingly, the reporter cells used in this study were not
Vγ9Vδ2 TCR-transduced murine hybridoma cells as described
above but Vγ9Vδ2 T lymphocytes generated from RAG knock-out
mice transgenic for the Vγ9Vδ2 TCR B2G9, which were matured
in vivo by administration of anti-CD3 mAb (95, 96). An important
difference between data obtained with primary murine reporter
cells expressing the Vγ9Vδ2 TCR B2G9 and Vγ9Vδ2 TCR-MOP
transduced reporter cells is that the agonistic mAb 20.1 was not
stimulatory but inhibitory for the transgenic mouse cells. First
results of our group obtained with TCR transductants suggest
that this difference reflects variation of the TCR clonotypes, which
stands against the idea of mAb 20.1 being a general activator
of Vγ9Vδ2 T cells. Nevertheless, to our knowledge, there is no
published data on determination of frequencies of mAb 20.1 vs.
PAg-reactive cells or direct comparison of sensitivity of differ-
ent TCR clonotypes for either stimulus supporting this notion. If
TCR clonotypes do indeed differ in their sensitivity to both types
of stimuli, it would affect models on PAg or mAb 20.1 action.
Our interpretation of the presumed clonal differences would rely
on substrate competition and inherent qualities of different TCR
clonotypes. In the former case, we hypothesize that upon treat-
ment of cells with PAg or mAb 20.1 BTN3A1 adopts a new
conformation, which somehow allows binding of Vγ9Vδ2 TCR
to BTN3-ED-PAg or mAb complex or to BTN3-ED-associated
cell surface molecules(s). This conformation could differ to some
extent after exposure of the cell to PAg or mAb 20.1 whereby mAb
20.1 might inhibit conversion into the PAg induced conforma-
tion. As a result, some TCR clonotypes cannot bind to the mAb
20.1-induced conformation. Indeed, one could imagine that mAb
20.1-binding “freezes” BTN3-ED in a conformation (93), which
is distinct from the PAg-induced one (93, 95). Considering inher-
ent qualities of TCR clonotypes as the basis for their differential
capacity in recognizing BTN3A1-ED-PAg complex or BTN3-mAb
complex, we propose or speculate that some Vγ9Vδ2 TCR, e.g.,
TCR B2G9 preferentially bind to a complex of PAg bound to the
BTN3A1-ED, whereas others would preferentially bind to the con-
formationally changed BTN3A1 whose ED does not need to be in
complex with the PAg. Consistent with this model would be that
the area covered by the mAb 20.1 is rather near to the hypothetical
PAg-binding site discussed in the next paragraph. Consequently
for some TCR mAb 20.1 would compete with binding of the
Vγ9Vδ2 TCR to a BTN3A1-PAg complex while for others mAb
20.1 would still be stimulatory.
De Libero and coworkers (95) provide also a wealth of data in
favor of a direct binding of PAg to BTN3A1-ED and of bind-
ing of BTN3A1-PAg complexes to the Vγ9Vδ2 TCR: (i) IPP
and HMBPP induce a substantial IFNγ secretion by the murine
reporter cells cultured in BTN3A1-V domain coated culture plates.
(ii) Mass spectrometry data of BTN3A1-V incubated with IPP
is consistent with a BTN3A1-IPP complex of 1:1 stoichiometry.
(iii) Plasmon resonance analysis of PAg binding to BTN3A1-V
domain allowed calculation of K d values. These are considerably
lower than that of MHC-peptide complexes: 66.9× 10−6 M for
binding of BTN3A1-V to IPP and 3.06× 10−6 M for binding of
BTN3A1-V to HMBPP. (iv) Crystal structures of complexes gen-
erated from BTN3A1-V and IPP or HMBPP, respectively, identify
a shallow Ag-binding groove. The amino acids proposed to inter-
act with HMBPP or IPP respectively are marked in Figure 1A.
(v) Plasmon resonance analysis revealed a low affinity binding of
recombinant Vγ9Vδ2 TCR multimers (dextramers) (TCR G2B9)
to immobilized eukaryotic recombinant BTN3A1-ED (vi) Surface
enhanced Raman scattering demonstrates binding of monomeric
TCR to BTN3A1 with a K d of 34× 10−5 M in the presence and
93× 10−5 M in the absence of IPP. All these data can be interpreted
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as evidence that BTN3A1 serves an antigen-presenting mole-
cule (95). A simplified version of this hypothesis is depicted in
Figure 2B.
The results and conclusions (95) on BTN3-binding to PAg and
Vγ9Vδ2 TCR summarized in the previous paragraph are heavily
disputed by proponents of the “allosteric model” (94). In their
recent publication, the groups of Adams and Scotet/Bonneville,
respectively, give detailed account on failed attempts to detect
PAg-binding to the BTN3-ED and of Vγ9Vδ2 TCR (TCR-G115)
dextramers to immobilized BTN3-ED. Furthermore, their paper
opposes the interpretation of the BTN3-V domain crystallized in
presence of PAg as BTN3-PAg complex (94). Based on their analy-
ses of the B30.2 domain and their own negative data on PAg- and
TCR-binding, BTN3A1 is refuted as an “antigen-presenting mol-
ecule.” Instead, they propose in the discussion section: “a model
where PAg binding to the BTN3A1 ID results in recruitment of
additional primate-specific factors and/or rearrangement of the
BTN3A1 extracellular domain that generates a stimulatory signal
directly detected by the Vγ9Vδ2 TCR. This is similar to “Model 2”
proposed by Morita and colleagues” (94). The paper of the Morita
group (80) mentioned here describes their failed attempts to show
binding to BTN3-ED by the use of photo-activatable HMBPP
and develops models to explain lacking PAg-binding to BTN3-ED
despite its crucial role for the activation of Vγ9Vδ2 T cells.
Some of the data and interpretations reported by the pro-
ponents of either model can be reconciled and others not. For
example, both agree on the importance of the ID for BTN3A1
mediated PAg activation, and in principle the data on PAg-binding
to the BTN3-ID could be adapted in a model with BTN3A1 as an
antigen-presenting molecule in following ways: (1) PAg-binding
to the BTN3A1-ID may result in intracellular trafficking, e.g.,
recruitment of a molecule which enables loading of PAg to the
BTN3A1-ED and/or involved in proper cell surface distribution
of BTN3A1 with the PAg loaded BTN3A1-ED. (2) Another pos-
sibility could be that PAg-binding to the BTN3A1-ID induces a
conformational change facilitating formation of the BTN-ED-PAg
complex or stabilization of such a complex. Concerning the dissent
on crystallographic and binding data it would be most desir-
able – and important for the research community – if controversies
on the validity of experimental procedures and their interpreta-
tion were solved, e.g., by collaborative attempts of both parties
to reproduce data with exchanged reagents, e.g., the different
BTN3 preparations and the different TCR clonotypes (TCR-G115
vs. TCR-G2B9). In addition, completely different experimental
approaches such as the identification of cofactors controlling PAg-
mediated activation by genetic methods might lead to new insights
and perspectives and help to solve this controversy.
EVIDENCE FOR CHR 6 ENCODED GENE(S), WHICH IN
ADDITION TO BTN3A1 ARE MANDATORY FOR
PAg-MEDIATED ACTIVATION
A first hint that BTN3A1 alone is not the only molecule expressed
in primates required for PAg mediated activation comes from
experiments where BTN3A1-transduced murine cells pulsed with
zoledronate failed to activate human Vγ9Vδ2 T cells (94). Never-
theless, these negative results need to be met with caution since
in this xenogeneic setting co-stimulatory receptors and adhesion
molecules required for Vγ9Vδ2 TCR-mediated activation might
miss their partners on the murine cell and activation may be
incomplete.
To solve this problem, murine reporter cells provide a valu-
able tool. We tested mouse-human hybridomas generated in our
laboratory for their capacity to activate reporter cells (TCR-MOP
transductants) (97) similarly, as it was done in (95). Consistent
with the localization of BTN3A1 on chromosome 6 (Chr. 6) only
hybridoma carrying the human Chr. 6 were able to induce PAg-
dependent Vγ9Vδ2 TCR responses. To test whether BTN3A1 alone
or BTN3A1 and other genes on Chr. 6 allow the PAg-mediated
stimulation and whether the same accounts for mAb 20.1-induced
activation, different types of Chinese hamster ovary (CHO) cells
were tested. We compared CHO cells and CHO cells containing
human Chr. 6 and the BTN3A1 transductants of either cell type.
In a nutshell, Chr. 6 was found to be sufficient and mandatory
to induce activation in the presence of HMBPP and zoledronate
while BTN3A1 alone allowed mAb 20.1-induced activation even
in the absence of Chr. 6 (97).
These data as well inhibition studies with BTN3-specific anti-
bodies are in full agreement with the pivotal role of BTN3A1 in
PAg-mediated activation but imply also the existence of one or
more human gene(s) controlling PAg-action, which are missing
in rodent cells. Such gene(s) could be involved in PAg-loading
onto BTN3A1 analogous to the TAP being mandatory for MHC-
class I mediated peptide-presentation. Other possibilities would
be, e.g., control of BTN3A1 related signaling pathways steering cel-
lular distribution of BTN3A1 or a factor X directly associated with
BTN3A1. In any case identification of these molecules in primates
will be essential for the design of rodent models with functional
Vγ9Vδ2 T cells, which can be expected to provide fresh insights of
Vγ9Vδ2 T cell physiology and facilitate preclinical research on
Vγ9Vδ2 T cells and Vγ9Vδ2 T cell-activating drugs (97). The
search for such molecule(s) could be facilitated by the murine
reporter cells (95, 97), which allow functional screens for the
missing genes, e.g., of rodent-human radiation hybrids containing
fragments of human Chr. 6 or human expression libraries.
An important implication of the finding that mAb 20.1 permits
Vγ9Vδ2 TCR-mediated activation by BTN3A1 expressing rodent
cells is that species (human) specific gene(s) can be dispensable
for PAg-independent Vγ9Vδ2 TCR-mediated activation. We sug-
gest that mAb 20.1 induces a conformational change of BTN3A1,
which allows the Vγ9Vδ2 TCR to directly interact with BTN3A1
or a highly conserved molecule, which upon mAb 20.1 incubation
interacts with BTN3A1 and is then recognized by the TCR.
We tested also CD69 up-regulation of human Vγ9Vδ2 T cells
with PBMC co-cultured with different CHO cell variants pulsed
with zoledronate. Only co-cultures with Chr. 6 consomic CHO
cells induced a Vγ9Vδ2 T cell specific activation. Interestingly, we
failed to detect CD107a induction suggesting that in this setting
Vγ9Vδ2 TCR-mediated activation is incomplete (97). This is of
interest since Sandstrom et al. (94) who tested another xenogeneic
setting namely co-culture of primary Vγ9Vδ2 T cells with zole-
dronate or mAb 20.1 pulsed BTN3A1-transduced murine cells
used CD107a expression as read out and might have missed a
partial activation. Not excluded can be that BTN3A1-transduced
CHO cells, which are of hamster origin might express species- or
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cells-specific factors that are missing in murine BTN3A1 transduc-
tants (94) and allowed activation of our reporter cells (TCR-MOP
transductant).
Vγ9Vδ2 TCR: THE NEGLECTED INTERACTION WITH PROTEIN
ANTIGENS
The identification of PAg as activator for the vast majority of
Vγ9Vδ2 T cells does not exclude other physiological modes of
TCR-triggered Vγ9Vδ2 T cell activation. In a series of studies
He and colleagues investigated tumor infiltrating γδ T cells, i.e.,
especially malignancies of ovarial origin, and identified specific
ligands whose recognition depended largely on the CDR3δ and
CDR3δ flanking regions of the TCR (98–103). This was demon-
strated with help of TCR transductants but also with Ig constructs
with implanted CDR3δ, which bind to tumors in vitro and trig-
ger tumor elimination in xenografted mice (103). Among the
proposed antigens were MutS homolog 2, hsp 60 (99), and the
NKG2D ligand ULBP-4 (100). In one case tumor-specific and PAg-
mediated activation were compared and mutagenesis of amino
acid 97 in the CDR3δ abolished PAg but not an anti-tumor
response (102). This CDR3δ-controlled recognition is reminiscent
of that of T22 molecules by murine γδ TCR (12, 104) and could
also be important for other human γδ T cells. In any case, apart
from its therapeutic potential the possibility of PAg-independent
tumor recognition by Vγ9Vδ2 T cells demonstrates a function of
Vγ9Vδ2 T cells beyond that of a sensor of metabolic aberrations
or of microbial metabolites (69). Indeed, it is rather likely that
such (oligo)clonal responses might have been missed in the analy-
sis of PAg-responding cells given the presumed low frequency of
such protein antigen-specific Vγ9Vδ2 TCR in comparison to PAg-
reactive cells. Furthermore, these oligoclonal PAg-independent
responses might contribute to the changes in the Vγ9Vδ2 T cell
repertoire seen during infections with HIV or with Mycobacterium
tuberculosis (49, 105).
Vγ9Vδ2 TCR AND BTN3 IN PRIMATES
Monkeys including hominids possess Vγ9Vδ2 TCR and functional
BTN3A1 genes (80, 93, 106, 107). PAg reactivity of Vγ9Vδ2 T cells
has been directly demonstrated for simian species (simiiformes),
which include the new world monkey Nancy Ma’s night mon-
key (Aotus nancymaae) (108) and the common marmorset (Cal-
lithrix jacchus) (109) and the old world monkeys rhesus macaque
(Macaca mulatta) (110) and cynomologous macaque (Macaca fas-
cicularis) (111), which bear a hydrophobic amino acid at position
97 of delta chain and Vγ9JP rearrangements. Human and most
primate species have a K(Lysine)KIK motif in JP, which is some-
times changed to R(Arginine)KIK without apparent consequences
for PAg reactivity (107, 110).
An update in September 2014 of our previous searches (107)
identified translatable Vγ9, Vδ2, and BTN3A1 sequences in lower
primates for the representative of non-simiiforme haplorrhini, the
philippine tarsier (Carlito syrichta). The same was found for aye
aye (Daubentonia madagascariensis) and the gray mouse lemur
(Microcebus murinus) representing the two lemur clades of the
strepsirrhini suborder. The BTN3A1 sequences were largely con-
served in the proposed PAg-binding motif of the BTN3-ED and in
the BTN3-ID. The BTN3-ID of aye aye and tarsier showed the
H351R substitution, which abrogates PAg-binding of BTN3A3
(Figure 1). Therefore, it would be interesting to learn whether
this also leads to loss of PAg-binding or is compensated by other
sequence changes. If PAg-binding of the BTN3-ID was indeed lost
and if PAg involvement is needed to maintain the typical Vγ9Vδ2
TCR repertoire then one would expect consequential effects on
this repertoire, e.g., less or no Vγ9JP rearrangements.
Vγ9, Vδ2, AND BTN3 CO-EMERGED AND MAY HAVE
CO-EVOLVED IN PLACENTAL MAMMALS
Studies on rodent genomes and on TCR expressed in farm ani-
mal species (cow, pig, horse) provided no evidence for Vγ9 or Vδ2
homologs, and it was generally assumed that Vγ9Vδ2 T cells might
be restricted to (higher) primates. Taking advantage of increas-
ing number of public data genome data bases, especially the 29
mammals project, which covered all mammalian orders (112),
we blasted against genomes of Eutherian mammalian species in
search for genes homologous to human Vγ9, Vδ2, and BTN3-ED.
We asked for at least 80% sequence coverage and 70% nucleotide
identity to human genes in order to identify new species as poten-
tial Vγ9Vδ2 T cell carriers. Homology was confirmed by reverse
blasting and different types of phylogenetic trees were generated.
Most of these results have been published recently (107) but we
take the opportunity of this paper to present changes resulting
from recent updates in the database and from inclusion of the
BTN3-ID in our analysis (Figure 1).
Truly surprising results were obtained from the analysis of non-
primate species. The timing of the origin of placental mammals
is subject of a protracted debate and has been estimated to occur
between 165 and 65 million years ago (113–115). Nevertheless,
there is consensus that Xenathra – represented in the databases
by the nine-banded armadillo (Dasypus novemcinctus) and the
two fingered sloth (Choloepus hoffmanni) belong to a clade dis-
tinct from Boreoeutheria, which represents the other placental
mammals. Thus, detection of a gene in a species of Xenathra and
Boreoeutheria proves its presence in a common placental prede-
cessor. Exactly, this is seen for Vγ9, Vδ2, and BTN3-ED since they
are found in sloth and armadillo. While TCR-V genes were rather
conserved (107), Figure 1 shows that BTN3-ED of sloth lacks a
major part of the V domain while that of armadillo lacks parts
of the C domain. A BTN3-ID like domain could not be identi-
fied for sloth and the B30.2 domain of armadillo was identified as
a homolog of BTN2-ID. With the current knowledge on BTN3-
structure-function relationship and PAg-mediated Vγ9Vδ2 T cell
activation, it seems unlikely that these molecules could function as
proposed for human BTN3. Consequently, we would not expect
maintenance of typical Vγ9Vδ2 T cells (e.g., dominance of the
characteristic Vγ9JP rearrangements) but if such cells were found,
then they should be tested for PAg-reactivity or -binding to other
ligands. Testing is especially relevant for armadillo, since it is a
natural host Mycobacterium leprae, an important human pathogen
and potential target for Vγ9Vδ2 T cells (116).
Many of the tested genomes had lost all three genes. This was
true for lagomorphs and most rodents and explains why PAg-
reactive cells have never been observed in the classical small animal
models (rat, mouse, guinea pig, and rabbit). A notable exception
could be the 13-lined squirrel (Spermophilus tridecemlineatus),
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which conserved a translatable Vγ9 and a presumably functional
BTN3 (Figure 1) but lacks a Vδ2. Therefore, it will be of spe-
cial interest to learn whether this Vδ2 is truly missing or whether
the searched database is incomplete. Species of other orders such
as those representing Bovidae (cow, sheep, goat, tibetan ante-
lope) kept all three genes but at least one of them was either not
translatable (e.g., BTN3-ID of tibetan antelope) or otherwise non-
functional as in the case of the horse (Perissodactyla) whose Vγ9
and Vδ2 genes lacked one of the cysteine required for Ig domain
disulfide bond (107).
It is very striking that all species (11 species representing 9
families representing 3 of the 4 mammalian superorders) with
translatable Vγ9 and Vδ2 TCR gene possess translatable BTN3-
ED. The inverse correlation is not as strict, since BTN3A1 of
horse (Equidae), white rhinoceros (Rhinocerotidae), several bats
(Vespertilionidae), and the thirteen-lined squirrel (Sciuridae) are
translatable, although the species lack either functionalVγ9 and/or
Vδ2 genes. However, inspection of BTN3-ID (Figure 1) of horse,
rhinoceros and bats shows considerable differences in the pro-
posed PAg-binding site suggesting loss of PAg-related function.
These species show non-conservative substitutions in the pro-
posed extracellular and intracellular PAg-binding sites while the
other species with a complete and translatable BTN3-ED showed
no or only conservative changes (K to R and vice versa). Altogether,
the data suggest an interdependence in conservation of func-
tion between Vγ9, Vδ2, and BTN3 genes and indicate molecular
co-evolution of Vγ9Vδ2 TCR and BTN3 (117).
ALPACA (VICUGNA PACOS ) AS MODEL TO STUDY Vγ9Vδ2 T CELLS IN A
NON-PRIMATE SPECIES
Of the nine species originally found to possess translatable Vγ9,
Vδ2, and BTN3-ED genes (107), alpaca was the only one accessi-
ble for further analysis. Vγ9-Cγ PCR products from PBMC cDNA
were cloned and although different Jγ segments were identified,
90% of the clones showed a JP rearrangement. The primate KKIK
or RKIK motif is largely conserved in the three alpaca JP, which
have a KTIK or RTIK motif. In contrast to human Vγ9Vδ2 T cells,
the Vδ2 gene rearranged (25 out of 25 clones) always with a single
Jδ gene, which is highly homologous to human Jδ4 (TRDJ*04.)
The amino acids L, I, V, and G at position 97, which are typical
for PAg reactive human Vγ9Vδ2 TCR were found in 8 out of 17
clones bearing alpaca Vδ2 chains. Similar to human, alpaca Vδ2
chains also show high diversity in CDR3 lengths ranging from
11 to 18 amino acids (38, 107), while CDR3γ length is rather
restricted (107). Transduction of 58α-β-cells (BW58) with full
length alpaca Vγ9 and Vδ2 TCR chain genes led to their cell sur-
face expression as assessed by surface staining for murine CD3
and detection of IL-2 upon culture with immobilized anti-CD3
antibodies. Due to lack of appropriate reagents, the formal proof
of cells concomitantly expressing Vγ9 and Vδ2 TCR chains is still
missing.
Nevertheless, at least with respect to BTN3A1 and the TCR
genes, there is currently no obvious reason to assume that PAg
could not activate alpaca Vγ9Vδ2 T cells. Indeed, the BTN3A1
has been cloned and expressed and showed complete identity
with human BTN3 in the published intracellular- and extra-
cellular PAg-binding sites (118). The functionality with respect
to PAg-responses will be tested with γδ TCR transductants and
camelid stimulator cells but also with alpaca PBMC.
If PAg-reactivity can be confirmed, alpaca will provide an
outgroup allowing identification of common denominators of
PAg-reactivity of Vγ9Vδ2 T cells, and it will allow analysis of
conservation of the molecular mechanisms of PAg-dependent
stimulation or presentation, respectively. If PAg-reactivity is miss-
ing, then interesting questions arise. Are there alternative modes
of Vγ9Vδ2 T cell activation and are they also BTN3A1-dependent?
If there is a BTN3-dependent Vγ9Vδ2 T cell activation, new ques-
tions arise such as, did other molecules take over the role of PAg
and can introduction of human genes (favorably encoded on chro-
mosome 6) generate a BTN3A1-dependent PAg-response similar
to that seen in humans?
IDENTIFYING CANDIDATE SPECIES FOR DENDRITIC
EPIDERMAL T CELLS BY INVESTIGATING γδ TCR GENES AND
Skint1 HOMOLOG IN MAMMALS
At the end of this review, we want to discuss a possible co-evolution
of γδTCR genes and their relation to another member of the buty-
rophilin family. Dendritic epidermal T cells (DETC) present an
extreme case of a highly specialized γδ T cell population, which so
far has only been found in mice and rats (28, 119, 120). As the name
indicates these T cells have dendritic shape and reside in the epider-
mis. They appear as the earliest T cells during development in the
fetal thymus and subsequently migrate to skin. In the skin, they
fulfill TCR-dependent and TCR-independent functions in body
barrier surveillance including control of tumor development, skin
repair, and allergy control. A hallmark of these cells is expression
of a single TCR, which with unique rearrangements containing
Vγ3 and Vδ4 (IMGT-nomenclature; other common nomencla-
tures are Vγ3Vδ1 and Vγ5Vδ1). Canonical DETC can be replaced
by cells with a polyclonal TCR repertoire but these do not fulfill
all of their functions (15, 25, 30). Mandatory for the development
of canonical DETC is the molecule Skint1, which is a member of
the butyrophilin family. It consists of a V-C domains containing
extracellular domain and a three times transmembrane-spanning
domain (31, 121, 122). Its role in DETC development was discov-
ered by analysis of FVB/N mice from Taconics laboratories. These
mice showed changes in the DETC TCR repertoire,which were cor-
related with a skin phenotype (spontaneous ear inflammation and
exaggerated irritant contact dermatitis response to tetradecanoyl-
phorbol acetate). The genetic basis of this phenotype is a termina-
tion mutation in codon 324 of Skint1 immediately upstream of the
third transmembrane domain of the molecule (31, 121). In a recent
study on structure-function relationship of Skint1, it was found
that a tightly regulated cell surface expression on medullary thymic
epithelial cells was mandatory for efficient DETC development.
Furthermore, mutagenesis and domain exchange proved that each
Skint1 domain is non-redundant, including a unique decamer
specifying V-domain processing (122) (marked in Figure 3).
Prompted by the striking concomitant conservation of TCR-V
genes and BTN3A1 and the success with identification of alpaca
as a candidate for a Vγ9Vδ2 T cell positive species, we decided to
search for homologs of DETC TCR-V genes Vγ3 and Vδ4 and of
Skint1 as a gene controlling DETC development using the same
methods as for BTN3 and Vγ9Vγ2 TCR genes (107). Homologs
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FIGURE 3 | Alignment of human BTN3A1 (V-C) and B30.2 domain.
(A) ClustalW2 amino acid alignment of V-C domains of mouse Skint1
extracellular domain with respective homologous sequence identified from
WGS database at NCBI. Underlined bold 10 amino acids stretch is predicted
to confer functionality for mouse Skint1 (122). (B) ClustalW2 amino acid
alignment of V-C domains of mouse Skint1 extracellular domain with its
paralogs. Underlined bold 10 amino acids stretch is predicted to confer
functionality for mouse Skint1 (122). Species were abbreviated as Mou,
Mouse; CGM, Cape golden mole; PVo, Prairie vole; GHa, Golden hamster;
CHa, Chinese hamster; GHB, Greater horseshoe bat.
for at least one of the three genes were identified in 69 species, all of
them were Eutheria. No hits were found for Xenathra but the cape
golden mole was identified as an afrotherian species being “triple
positive.” In case of the TCR-V genes, the assignment was always
clear. In case of Skint1, forward blasting of the V-C domains let to
identification of genes as Skint1 homolog, which in reverse blast
turned out to be Skint2 or Skint3 homologs. We marked this in our
table (Table S1 in Supplementary Material) but the limited knowl-
edge about Skint structure and mode of action does not allow to
make any predictions to which extent the Skint homologs in these
species are redundant – which at least in mouse they are not (122).
Also statements on translatability have to be taken with some cau-
tion since transmembrane encoding exons were not included in
the search.
Nevertheless, the retrieved data (Table S1 in Supplementary
Material and Figure 3) could help to identify non-murine species
as candidates for a search for rearranged DETC TCR genes and
functional Skint: prime candidates are rodent species, which do
not belong to the family of murideae but are still phylogeneti-
cally not too distant. These would be the two hamster species.
Also interesting but unfortunately not yet sequenced at genomic
level is the cotton rat (Sigmodon hispidus) and therefore not to
be found in the Table S1 in Supplementary Material and Figure 3.
This“new world mouse”species is a well-established animal model
for a number of infectious diseases (123). Triple positive members
were also found in other mammalian superorders than the rodent-
containing Euarchontoglires. These are Afrotheria with the golden
cape mole (Chrysochloris asiatica) and Laurasiatheria species with
the greater horseshoe bat (Rhinolopus ferrumequinum) and the
cow (Bos tauris). Nearly, all bats (Chiroptera) carry translat-
able Vγ3, Vδ4, and either Skint1 or Skint2. Finally, the cow was
also triple positive and was the only Artiodactyla species with a
translatable Skint. Given the limits of our data-base search, how-
ever, at first it needs to be tested whether the latter is still functional.
If expression of a Skint1 can be confirmed, it will be of interest
to test whether a cow DETC population might be hidden among
other populations such as the circulating polyclonal dermal γδ T
cells or the small epidermal γδ T cell population (124).
Nevertheless, despite all possible pitfalls in database analysis, we
are confident that comparative analysis of TCR genes and genes of
putative TCR ligands or of molecules controlling development and
function of non-conventional T cells will allow to identify genetic
or functional homologs to human non-conventional T cells. The
identification of such homologous populations in phylogenetic
distant species or species with different life style could help to
identify common themes on preservation and flexibility of genes
and of functions of such cells. Going back to human beings (or
mice) and seeing old acquaintances in a new light may help for a
better understanding of the human system and identification of
targets of genetic and immune-intervention.
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